Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.97 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.97 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.97 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.97 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.97 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.97 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.97 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.97 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.97 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.97 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517051 | 0.92 | HDAC3 (0.87) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL17252161 | 0.89 | HDAC3 (0.77) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL22923581 | 0.89 | HDAC3 (0.77) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL31635263 | 0.88 | HDAC1 (0.83) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL23798902 | 0.86 | HDAC3 (0.72) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL30345218 | 0.85 | HDAC1 (0.71) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL18376685 | 0.85 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL14328271 | 0.84 | HDAC8 (0.70) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL3026241 | 0.84 | HDAC3 (0.74) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL4461588 | 0.84 | HDAC1 (0.69) | HDAC1HDAC6HDAC3HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10189858-B2 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180118758-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX, LLC (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189858-B2 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | EGLN3, AQP3, AQP4 | HDAC1 1277/4885HDAC6 96/4885HDAC3 186/4885 |
| US-20180118758-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, AQP3, AQP4 | HDAC1 1277/4885HDAC6 96/4885HDAC3 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.